Earlier today, Professor Wolfgang Wick (University of Heidelberg, Germany) presented data from the recently completed European Organization for Research and Treatment of Cancer (EORTC) 26101 randomized phase III trial that compared a treatment of Lomustine (Lom; CCNU) against the combination of Bevacizumab plus Lomustine in recurrent GBM patients. Professor Wick’s presentation was made at the 2015 Society for Neuro-Oncology (SNO) Annual Scientific Meeting in San Antonio, Texas.
Results of the study showed that the Bevacizumab plus Lomustine treatment DOES NOT improve survival in patients with progressive GBM, despite prolonging progression free survival. Professor Wick, who was the clinical coordinator of the study, proposed that a future challenge will be to identify those patients who may benefit from treatment with Bevacizumab.
Additional data, including patient-reported outcomes as well as genomic and epigenetic data on the patients, will be provided later when the full report of the trial is completed.
National Brain Tumor Society staff on hand at SNO 2015 are talking with a number of researchers and key advisors about these results and we will provide further information and perspective on this news in the coming days. We will keep you updated on the latest information. Additionally, our staff will continue to keep the community aware of any and all research developments from SNO 2015.